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Although the primary signal for the activation of steroid hormone receptors is binding of hormone, there is
increasing evidence that the activities of cell signaling pathways and the phosphorylation status of these
transcription factors and their coregulators determine the overall response to the hormone. In some cases,
enhanced cell signaling is sufficient to cause activation of receptors in medium depleted of steroids. Steroid
receptors are targets for multiple kinases. Many of the phosphorylation sites contain Ser/Thr-Pro motifs
implicating proline-directed kinases such as the cyclin-dependent kinases and the mitogen-activated kinases
(MAPK) in receptor phosphorylation. Although some sites are constitutively phosphorylated, others are
phosphorylated in response to hormone. Still others are only phosphorylated in response to specific cell
signaling pathways. Phosphorylation of specific sites has been implicated not only in overall transcriptional
activity, but also in nuclear localization, protein stability, and DNA binding.The studies of the roles of
phosphorylation in coregulator function are more limited, but it is now well established that many of them
are highly phosphorylated and that phosphorylation regulates their function.There is good evidence that
some of the phosphorylation sites in the receptors and coregulators are targets of multiple signaling pathways.
Individual sites have been associated both with functions that enhance the activity of the receptor, as well
as with functions that inhibit activity.Thus, the specific combinations of phosphorylations of the steroid
receptor combined with the expression levels and phosphorylation status of coregulators will determine the
genes regulated and the biological response.
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Introduction
Steroid hormone receptors are hormone-activated
transcription factors whose activities are also modulated
by posttranslational modifications including
phosphorylation [Faus and Haendler, 2006]. In the
absence of hormone, receptor monomers associate with
heat shock protein complexes and as a rule are minimally
phosphorylated (Figure 1). Upon binding hormone, the
receptors dimerize, cytoplasmic receptors translocate to
the nucleus and the receptors bind to sequence-specific
hormone response elements (HRE).Typically, hormone
binding and localization to specific DNA binding sites is
accompanied by an increase in receptor phosphorylation.
The receptors recruit a series of coactivator complexes
that facilitate chromatin remodeling, recruitment of Pol II
(polymerase II), and transcription of specific target genes.
Phosphorylation of coactivators and Pol II is also integral
to regulation of transcription. Moreover, some of the
proteins recruited to the chromatin by steroid receptors
are themselves kinases that can modify histones or other
proteins associated with chromatin.
In some cases, upon hormone binding, a portion of the
cytoplasmic receptor associates with and activates Src
kinase, leading to activation of downstream signaling
[Edwards, 2005; Lange, 2004]. In addition, there is
evidence that a small fraction of some of the receptors is
associated with the cell membrane and hormone binding
induces activation of a variety of signaling pathways.
Structurally, the steroid receptors share many common
features [Evans, 1988], as shown in Figure 2.The
receptors all contain carboxyl terminal ligand binding
domains (LBD) that include a region termed activation
function 2 (AF-2), which is a site for coactivator binding
and thus is important for the induction of transcriptional
activity.The LBD is linked to the DNA binding domain
(DBD) by a hinge region (H) that contains a nuclear
localization signal.The DNA binding domains are the
most highly conserved regions of the receptors and each
contains two Zn
++ binding motifs.The amino terminal
domains (NTD) are the least conserved regions both in
sequence and in length, but all contain at least one region,
termed AF-1 (activation function 1), that is required for
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Review  Nuclear Receptor Signaling  |  The Open Access Journal of the Nuclear Receptor Signaling AtlasFigure 1.  Mechanism of steroid hormone action. In the absence of hormone, steroid receptor monomers (SR) are associated with heat shock
protein complexes (HSP) and are typically basally phosphorylated. Upon binding hormone, receptors dissociate from heat shock proteins, dimerize,
bind to target gene-specific sites containing hormone response elements (HRE), and recruit a series of coactivator complexes to regulate target gene
transcription. Site-specific phosphorylation of receptors increases subsequent to hormone binding, with some increases occurring rapidly, and others
with delayed kinetics. Upon steroid binding, some receptors also interact with Src and MNAR, activating Src and downstream kinases including p42/p44
MAPK. Membrane-associated receptors (mSR) also bind hormone and initiate signaling cascades.While some of these are classical steroid receptors,
others bear no homology to the steroid receptor superfamily.
optimal transcriptional activity. Most of the
phosphorylation sites identified in steroid receptors are
located in the NTDs of the receptors, although many have
at least one phosphorylation site in the hinge region, and
there are limited reports of phosphorylation sites in the
hormone and DNA binding domains. Shown in Figure 2
are the best characterized phosphorylation sites in the
human steroid receptors. Others have been proposed
based on in vitro studies and additional sites have been
identified in steroid receptors from other species.
Consequently, there are likely to be additional unidentified
sites in at least some of the human steroid receptors.
Several strategies have been used to elucidate the roles
of cell signaling in steroid receptor action and in crosstalk
between steroid receptors and growth factor signaling
pathways.The first is simply to alter the activity of a
signaling pathway using activators or inhibitors and to
measure the effect on steroid receptor activity. Changes
identified using this technique demonstrate a role for the
pathway in regulating receptor action, but the target may
be an associated protein rather than the receptor, or a
combination of the receptor and other proteins. A second
approach is to measure the activity of receptors containing
alanine substitutions for one or more of the serine or
threonine phosphorylation sites.This strategy requires
knowledge of the location of the phosphorylation sites.
While many have been located, others have yet to be
identified. Finally, a number of studies in recent years
implicate steroid receptors in the direct activation of cell
signaling pathways potentially modifying receptor function,
as well as inducing activation of target genes sensitive
to increased kinase activity.
Modulation of cell signaling pathways
alters steroid receptor activity
Ligand-independent activation
The most striking evidence for the potential importance
of cell signaling in steroid receptor action was the finding
that some steroid receptors can be activated in the
absence of measurable levels of hormones by treatments
that enhance activity of kinases or inhibit phosphatase
activities. Denner et al. first showed that 8-Br cAMP
treatment of cells transfected with a chicken progesterone
receptor (cPR) expression vector and a PR-responsive
reporter caused hormone-independent, but
cPR-dependent, activation of the reporter [Denner et al.,
1990b].This activation was independent of the four
characterized phosphorylation sites in cPR and 8-Br
cAMP did not induce phosphorylation of PR [Bai et al.,
1997]. However, subsequent studies revealed that 8-Br
cAMP caused activation of p42/p44 MAPK
(mitogen-activated kinase) and increased phosphorylation
of the p160 coactivator, SRC-1 (steroid receptor
coactivator-1); these SRC-1 phosphorylation sites
contributed to the ligand-independent activation [Rowan
et al., 2000]. Other signaling pathways also induce
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Review Phosphorylation in steroid hormone actionFigure 2.  Domain structures of steroid receptors. The numbers of the amino acids found at the boundaries in the individual receptors between
the NTD (amino-terminal domain), DBD (DNA binding domain), hinge region (H), and ligand binding domain (LBD) are indicated in the figure. Also
shown are the best characterized phosphorylation sites in the human steroid receptors.
activity.Treatment of transiently transfected cells with
dopamine activates a number of receptors including cPR
[Power et al., 1991] and ERα (estrogen receptor α) [Smith
et al., 1993] in the absence of their cognate ligands.
Treatment with the phosphatase inhibitor, okadaic acid,
also induces ligand-independent activation of cPR
[Denner et al., 1990b].There is evidence that these
alternate activation pathways are also functional in vivo.
For example, treatment with dopamine causes
PR-dependent induction of lordosis in female rats and
mice [Apostolakis et al., 1996; Mani et al., 1996; Mani et
al., 1994; Mani et al., 2006]. As expected for a
PR-dependent response, PR null mice are not responsive.
Estrogen receptor α
The responsiveness of receptors to cell signaling
pathways in the absence of hormone differs greatly.
Whereas the glucocorticoid receptor (GR) requires ligand
for activation, ERα is very responsive to cell signaling
pathways. Indeed, ERα in cells maintained in phenol
red-free, charcoal-stripped serum, utilized to
minimize/eliminate steroids, frequently displays
substantial basal transcriptional activity in the absence
of added ligand; this activity can be reduced by the use
of a pure anti-estrogen such as ICI 182780, showing that
the activity is dependent upon ERα [Smith et al., 1993].
There are multiple pathways for hormone-independent
activation of ERα. One of the best characterized of the
hormone-independent pathways for the activation of the
ERα is the EGF (epidermal growth factor)-dependent
activation of human ERα in transfected HeLa cells.
EGF-dependent activation induces phosphorylation of
Ser
118 in the amino terminus of ER [Kato et al., 1995].
Substitution of an alanine for the serine abrogates the
hormone-independent activation. However, substitution
of a glutamic acid, which provides a constitutive negative
charge, restores responsiveness to EGF, but does not
cause the receptor to become constitutively active
[Bunone et al., 1996].
Thus, EGF-dependent activation requires phosphorylation
of ERα at Ser
118, as well as phosphorylation of at least
one other target. One possibility is Ser
167 in ERα. EGF
treatment typically results in activation of Rsk downstream
of p42/p44 MAPK; Ser
167 is a substrate for Rsk [Clark et
al., 2001; Joel et al., 1998]. Other pathways are
independent of Ser
118 phosphorylation (or the
corresponding mouser Ser
122), demonstrating that there
are multiple means of activating ER independent of its
ligand [Patrone et al., 1998].
Androgen receptor
The androgen receptor (AR) also has the capacity to
respond to cell signaling pathways in cells grown in
medium depleted of hormone. Among the factors reported
to induce AR activity are EGF, KGF (keratinocyte growth
factor) [Culig et al., 1994], IL-6 (interleukin-6) [Hobisch
et al., 1998], and forskolin [Nazareth and Weigel, 1996],
an activator of protein kinase A. Overexpression of the
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Growth Factor Receptor 2), also induces AR activity [Craft
et al., 1999]. Activation of AR by cell signaling pathways
in the absence of normal levels of androgens likely
contributes to the recurrence of prostate cancer.The
recurrent tumors express high levels of AR and re-express
many AR target genes including PSA (prostate specific
antigen) (reviewed in [Agoulnik and Weigel, 2006]).
Several investigators have demonstrated that AR-positive,
androgen-independent cell lines that express PSA in
medium depleted of androgens still require AR for cell
growth and expression of PSA [Agoulnik et al., 2005;
Zegarra-Moro et al., 2002]. Because the AR sequence
does not differ from that of AR in androgen-dependent
cells, it is presumed that altered cell signaling is causing
aberrant receptor activation.
Potentiation of partial antagonist activity
Although some receptors show minimal responsiveness
to cell signaling pathways in the absence of ligand,
enhanced cell signaling often potentiates receptor activity
in the presence of a partial antagonist.Treatment with
8-Br cAMP causes the mammalian PR and GR
antagonist, RU486 (mifepristone), to act as a GR
[Nordeen et al., 1993] and a PR-B isoform [Beck et al.,
1993; Sartorius et al., 1994] specific agonist.The finding
that cell signaling pathways can induce
hormone-independent activation, can cause receptors to
be responsive to lower levels of hormone, and can cause
antagonists such as tamoxifen and RU486 to have agonist
activity, is particularly relevant in hormone-sensitive
cancers such as breast and prostate cancer. Signaling
pathways that enhance AR activity are often activated in
advanced prostate cancers [Gioeli et al., 1999; Gregory
et al., 2004; Gregory et al., 2005; Mellinghoff et al., 2004]
and HER2 signaling combined with overexpression of
AIB1 is one contributor to tamoxifen resistance in breast
cancer [Shou et al., 2004].
Modulation of agonist-dependent activity
The activities of specific kinases are also required for
hormone-dependent activation of steroid receptors,
although in many cases the targets of receptor action
have not been fully elucidated.This is an active area of
research and the studies are far from comprehensive.
The response of receptors to signaling pathways can be
cell-specific and it is likely that many of the responses
will also be target gene-specific. Although there are some
recent studies examining regulation of endogenous
genes, most of the information has been obtained using
transfected reporters.
Whereas cyclin-dependent kinases generally enhance
the activity of steroid receptors, the actions of other
kinases are receptor-specific. Surprisingly, some of the
cyclins function as receptor coactivators or corepressors
independent of their partner kinases. Only those actions
that require kinase activity are discussed below. Signaling
pathways that induce hormone-independent action or
cause antagonist/agonist switches also potentiate the
corresponding hormone-dependent activity and have
been discussed above.
Human progesterone receptor
Human PR requires Cdk2 (cyclin-dependent kinase 2)
for hormone-dependent activation of at least some of its
target genes [Narayanan et al., 2005a]. Inhibition of Cdk
activity with the cyclin-dependent kinase inhibitor
roscovitine blocks hormone-dependent induction of a
PR-responsive reporter or of the endogenous
metallothionein gene; reducing expression of Cdk2 also
strongly inhibits PR activity.The Cdk2 partner, cyclin A2,
is a PR coactivator that depends on binding Cdk for its
potentiation of PR activity. Although PR can be
phosphorylated by cyclin A2/Cdk2 in vitro [Knotts et al.,
2001], the potentiation of PR activity is independent of
PR phosphorylation [Narayanan et al., 2005a]. Rather,
the target is likely to be the p160 coactivator, SRC-1. In
ChIP (chromatin immunoprecipitation assays), roscovitine
treatment has no effect on the binding of either PR or
cyclin A to an MMTV (mouse mammary tumor-like virus)
promoter, but it prevents the hormone-dependent
recruitment of SRC-1 [Narayanan et al., 2005a].
Consistent with the idea that cyclin A/Cdk2 is important
for PR function, PR-dependent activation of the MMTV
promoter is cell cycle-dependent [Narayanan et al.,
2005b]. PR activity is highest in S phase, where cyclin A
is most highly expressed, and lower in early G1 or in
G2/M phase. In cells with low levels of the
cyclin-dependent kinase inhibitor, p27, overexpression
of activated Cdk2 induces hormone-independent
activation of PR and this hormone-independent activation
is blocked by mutation of Ser
400, a PR phosphorylation
site [Pierson-Mullany and Lange, 2004].
Other kinases and phosphatases also modulate PR
action, although their targets have not been elucidated.
Treatment with EGF, resulting in activation of p42/p44
MAPK, enhances hormone-dependent activity [Daniel et
al., 2007]. In contrast, activation of p38 MAPK by MKK6
inhibits PR activity [Proia et al., 2006]. Phosphatases also
potentiate PR activity.The PP1 and PP2A inhibitor,
okadaic acid, stimulates PR activity [Beck et al., 1992].
In contrast, overexpression of the phosphatase, PPM1D
(p53-induced serine/threonine phosphatase, protein
phosphatase 1D magnesium-dependent, delta isoform),
enhances PR activity; reducing expression of endogenous
PPM1D in MCF7 breast cancer cells inhibits PR activity
[Proia et al., 2006].
ERα and ERβ
Estrogen receptor activity is also modulated by cyclin
A/Cdk2, but the activity is dependent upon the ability of
the kinase to phosphorylate ERα [Rogatsky et al., 1999].
Signaling pathways that induce hormone-independent
activation also potentiate hormone-dependent actions.
There are additional reports of kinases regulating ER
activity in specific cell types. In contrast to its effects on
PR, activation of p38 MAPK enhances the activity of ERα
and increases its nuclear localization in endometrial cells
[Lee and Bai, 2002]. However, p38 MAPK has been
reported to play a role in ERBB2/ERBB3-dependent
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et al., 2005]. GSK3β (glycogen synthase 3β) enhances
ERα activity in neuronal cells [Mendez and
Garcia-Segura, 2006]. Phosphatases also play a role in
regulating activity. Overexpression of PP5 (protein
phosphatase 5) reduces Ser
118 phosphorylation in ERα
and transcriptional activation. Moreover, reducing
expression of PP5 enhances the transcriptional activity
of ERα [Ikeda et al., 2004].
Glucocorticoid receptor
Studies of GR show that cyclin-dependent kinases, Cdk1
and Cdk2, can phosphorylate GR in vitro and that GR
expressed in yeast lacking the corresponding kinase
activity is less active than in a wild type strain [Krstic et
al., 1997]. In contrast, a number of kinases inhibit GR
activity. JNK (Jun N terminal kinase) inhibits rat GR
activity through direct phosphorylation of GR [Rogatsky
et al., 1998a]. Similarly, GSK3 inhibits rat GR through
direct phosphorylation [Rogatsky et al., 1998b]; it has no
effect on human GR, which lacks the corresponding
phosphorylation site. Although p38 MAPK also inhibits
GR activity, its effects are independent of the previously
identified phosphorylation sites in GR [Szatmary et al.,
2004]. Similar to ERα, PP5 is a negative regulator of GR
activity [Zuo et al., 1999].
Androgen receptor
AR activity is also regulated by cyclin-dependent kinases.
Similar to PR, overexpression of cyclin A enhances AR
activity [Narayanan et al., 2005a]. Roscovitine reduces
AR activity and expression [Chen et al., 2006]. Although
roscovitine inhibits many cyclin-dependent kinases,
studies with more specific inhibitors suggest that Cdk1 is
the kinase required for optimal AR protein expression.
Consistent with a different cyclin-dependent kinase
requirement compared to PR, the cell cycle dependence
of AR activity exhibits a different pattern, with a decrease
in activity at the G1/S boundary [Martinez and Danielsen,
2002].
Cell signaling pathways regulate both the transcriptional
activity and the stability of AR protein. Although inhibition
of HER2 decreases AR protein levels and activity at low
levels of hormone, the downstream kinase(s) responsible
for regulating AR activity and expression has not been
identified. HER2 activates Akt, but constitutively active
Akt cannot compensate for inhibition of HER2 [Mellinghoff
et al., 2004].The role of Akt in AR action is controversial.
Some investigators have found that Akt enhances AR
activity, whereas others have reported that it inhibits AR
activity [Lin et al., 2003; Lin et al., 2001;Taneja et al.,
2005].Thus, actions of Akt are likely to be
context-dependent. Akt inhibits the activity of GSK-3, a
kinase that has been reported to inhibit AR activity [Salas
et al., 2004].Thus, in cells with high levels of GSK-3
activity, activation of Akt through inhibition of GSK-3 may
increase AR activity. Mitogen-activated protein kinases
(MAPK) also modulate AR activity. MEKK1, an upstream
activator of p42/p44 MAPK, increases AR activity
[Abreu-Martin et al., 1999]. In contrast, inhibiting either
JNK or p38 MAPK using siRNA for their upstream
activators, MKK4 and MKK6, increases the expression
of prostate specific antigen (PSA), an androgen-regulated
gene in LNCaP prostate cancer cells [Gioeli et al., 2006].
Steroid receptor coregulators
In addition to directly modifying the receptors, there is
increasing evidence that receptor activities are regulated
by changes in the phosphorylation state of coactivators
and corepressors. For example, the p160 coactivators
are extensively phosphorylated and are targets of multiple
signaling pathways. Sites in SRC-1 are important in
potentiating hormone-independent activities of chicken
PR and human AR [Rowan et al., 2000; Ueda et al.,
2002]. Phosphorylation of SRC-1 also plays a role in the
interaction between human PR and SRC-1 [Narayanan
et al., 2005a].The related p160 coactivator, TIF2
(transcription intermediary factor 2)/GRIP1 (glucocorticoid
receptor interacting protein 1)/SRC-2, is phosphorylated
by p42/p44 MAPK, and this phosphorylation plays a role
in potentiating AR activity [Gregory et al., 2004].
Phosphorylation of GRIP1 by p38 MAPK enhances its
potentiation of ERα activity [Frigo et al., 2006].The third
p160 coactivator, AIB1 (amplified in breast cancer
1)/SRC-3, plays a broader role in modulating the activities
of multiple transcription factors. It is highly phosphorylated
and different transcription factors, including steroid
receptors, require phosphorylation of subsets of the
phosphorylation sites for optimal potentiation of activity
[Wu et al., 2002;Wu et al., 2004]. In some cases, the
receptors themselves can alter phosphorylation of SRC-3.
Estradiol treatment of ERα-containing cells increases the
phosphorylation of SRC-3 at specific sites [Zheng et al.,
2005].
Phosphorylation of corepressors also influences their
ability to repress transcription. Phosphorylation of the
corepressor, SMRT (silencing mediator of retinoid and
thyroid hormone receptors), by MEKK1 (MEK kinase 1),
causes nuclear export, relieving repression [Jonas and
Privalsky, 2004]. MEKK1 also causes dissociation of
N-CoR (nuclear receptor corepressor) complexes from
androgen and estrogen receptors, enhancing
transcriptional activity [Zhu et al., 2006]. Other
coregulators are also phosphoproteins and altered cell
signaling is likely to influence association and activities
of these proteins as well.
Kinases as coactivators
The responsiveness of steroid receptor function to a
variety of cell signaling pathways suggests that there may
be means to preferentially enhance or inhibit the
phosphorylation of components of steroid receptor
pathways in addition to the changes induced by global
changes in kinase/phosphatase activities.The simplest
mechanism would be direct interactions of receptors or
coactivators with kinases or phosphatases, enhancing
proximity to other potential substrates in the pathway.
Indeed, one of the first candidate coactivators identified,
TIF1α, is a protein kinase whose phosphorylation is
enhanced upon interaction with activated nuclear
receptors [Fraser et al., 1998]. A novel nuclear protein
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that enhanced AR activity, but did not phosphorylate AR,
leading to the conclusion that it acts through
phosphorylation of AR coregulators or modification of
chromatin proteins [Moilanen et al., 1998]. Other, better
characterized kinases have also been found to be
associated with nuclear receptors. AR interacts with Cdk9,
a component of P-TEFb, a kinase that phosphorylates
the CTD (carboxyl terminal domain) of Pol II, facilitating
elongation of transcripts [Lee et al., 2001]. PR recruits
cyclin A/Cdk2 to the promoter of target genes. Inhibition
of its activity blocks transcription of an MMTV promoter
and prevents recruitment of SRC-1, but not recruitment
of another coactivator complex containing TRAP220
(thyroid receptor associated protein 220) [Narayanan et
al., 2005a].
Receptors also interact with phosphatases, thereby
limiting activity. AR interacts with small carboxyl terminal
domain phosphatase 2, which reduces the transcriptional
activity of AR [Thompson et al., 2006]. PP5 binds to ERα
and ERβ; reducing PP5 expression enhances induction
of a number of ERα target genes including c-myc and
pS2 [Ikeda et al., 2004]. Other phosphatases and kinases
are brought to receptor complexes by proteins that
interact with receptors. For example, IκK (IκB kinase)
associates with SRC-3, a substrate for the kinase; the
kinase regulates the activity of the coactivator [Wu et al.,
2002]. Kinase inhibitor studies show that Ser
118 is at least
in part phosphorylated by IκKα [Weitsman et al., 2006].
Thus, binding of SRC-3 to ERα may facilitate the
hormone-dependent phosphorylation of Ser
118.The
phosphatase, PP5, interacts with GR through hsp90
complexes and reduces GR phosphorylation. Reducing
expression of PP5 has target gene-specific effects on GR
activity [Wang et al., 2007] ranging from no detectable
effect to substantial inhibition of hormone-induced
transcription.
Receptor phosphorylation
Identification of phosphorylation sites
Early attempts to identify phosphorylation sites in steroid
receptors relied on radiolabeling followed by direct protein
sequencing or comparisons of the radiolabeling patterns
of wild type and mutant receptors [Bodwell et al., 1991;
Denner et al., 1990a; Le Goff et al., 1994; Zhang et al.,
1997; Zhang et al., 1995; Zhou et al., 1995]. More recent
approaches to the identification of sites have included
mass spectrometry [Gioeli et al., 2002; Knotts et al.,
2001].
All of the steroid receptors contain multiple
phosphorylation sites.The receptors are partially
phosphorylated in the absence of hormone and are more
highly phosphorylated after hormone treatment. Some of
the sites exhibit enhanced phosphorylation in response
to hormone, while phosphorylation of others is almost
exclusively hormone-dependent. Most of the sites are
serines or threonines in the amino terminal regions of the
receptors, although there is a positionally-conserved
Ser-Pro or Thr-Pro in the hinge regions of the steroid
receptors.This site has been shown to be phosphorylated
in chicken [Denner et al., 1990a] and human PR [Knotts
et al., 2001], mouse ERα [Lahooti et al., 1995], and
human AR [Zhou et al., 1995].Whether it is also
phosphorylated in other receptors has not yet been
determined. Most of these sites are located in Ser/Thr-Pro
motifs, indicating that the receptors are direct targets of
proline-directed kinases including the cyclin-dependent
kinases and the MAPK family, which is consistent with
studies showing that these kinases modulate receptor
activity. Sites identified as authentic in vivo sites in the
human steroid receptors are shown in Figure 2.
Some of the phosphorylation sites in steroid receptors
are conserved across species, whereas others are unique
to specific species.There is a GSK3β phosphorylation
site in rat GR that is absent in human GR [Rogatsky et
al., 1998b]. Chicken PR contains four Ser-Pro
phosphorylation sites [Denner et al., 1990a; Poletti and
Weigel, 1993] and all are in the regions common to the
PR-B and PR-A isoforms. In contrast, human PR is highly
phosphorylated.There are a number of phosphorylation
sites common to the PR-A and PR-B isoforms, but PR-B
contains at least four additional phosphorylation sites in
its unique amino-terminus [Knotts et al., 2001]. Although
Ser
294 is in the primary sequence of both PR-A and PR-B,
studies with a phosphorylation site-specific antibody
reveal that Ser
294 is phosphorylated only in the PR-B
isoform [Clemm et al., 2000].The two isoforms have
different biological activities and this difference may reflect
unique conformations in the amino-termini of the two
isoforms; alternatively, a protein may bind to the PR-A
isoform, thereby occluding the site.
In addition to the Ser/Thr-Pro sites, sites in other
consensus sequences have been identified. Additional
receptor sites include Ser
167 in ERα, a casein kinase II
consensus site [Arnold et al., 1994] that is also
phosphorylated by Rsk [Joel et al., 1998], as well as by
Akt [Shah and Rowan, 2005], and a site in PR (Ser
81),
which is in a consensus CKII site and can be
phosphorylated by CKII in vitro [Zhang et al., 1994].
Additional sites are detected when specific cell signaling
pathways are activated. For example, activation of p38
MAPK causes phosphorylation of Thr
311 in ERα [Lee and
Bai, 2002] and activation of Protein Kinase A (PKA)
induces phosphorylation of Ser
305 in ERα [Al-Dhaheri and
Rowan, 2007]. In cells with high Akt activity, AR Ser
213 is
phosphorylated in response to DHT (dihydrotestosterone);
this phosphorylation is inhibited by the PI-3K inhibitor,
LY294002, suggesting that the phosphorylation is
Akt-dependent [Taneja et al., 2005].
In addition to the Ser/Thr phosphorylation sites in steroid
receptors, there is limited evidence to support tyrosine
phosphorylation. In ERα, phosphorylation of Tyr
537 in the
hormone binding domain has been described, although
others have not detected phosphorylation of this site,
suggesting that the stoichiometry of phosphorylation may
be low and/or it is only phosphorylated under specific
conditions [Al-Dhaheri and Rowan, 2006; Arnold et al.,
1995].Two recent studies have shown that Src can
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534 in the amino-terminus of AR
and there is some evidence that other tyrosines can be
phosphorylated to a lesser extent [Guo et al., 2006; Kraus
et al., 2006]. Consistent with the failure to detect tyrosine
phosphorylation of AR previously, an analysis of AR in
LNCaP cells revealed that tyrosine phosphorylation in
response to hormone was a rapid and transient event.
Using a phosphorylation site-specific antibody, Guo et al.
have shown that the site is phosphorylated in AR in
prostate tumors [Guo et al., 2006].
Applications of phosphorylation site-specific
antibodies
Because each receptor is multiply phosphorylated,
identifying the kinases that phosphorylate the individual
sites in vivo has been challenging. Site-specific antibodies
have been made for a number of the sites and some are
now commercially available. Studies with these antibodies
reveal that some sites are targets for multiple kinases,
allowing the receptors to respond to a variety of stimuli.
For example, Ser
118 in ERα is phosphorylated by p42/p44
MAPK as a result of EGF treatment, but cyclin H/Cdk7
phosphorylates the site in response to hormone treatment
[Chen et al., 2000; Chen et al., 2002]. Similarly, p42/p44
MAPK phosphorylates Ser
294 in PR-B in response to EGF,
but hormone-dependent phosphorylation of the site occurs
despite blocking p42/p44 MAPK activation [Narayanan
et al., 2005b].
Site-specific antibodies have also been useful in resolving
whether candidate sites are authentic in vivo sites. Initial
studies in LNCaP prostate cancer cells failed to identify
Ser
213, a consensus Akt phosphorylation site in AR, as
an authentic in vivo phosphorylation site [Gioeli et al.,
2002]; however, Ser
213 is phosphorylated by Akt in vitro
[Lin et al., 2001]. Subsequent studies with a site-specific
antibody revealed that Ser
213 is phosphorylated in wild
type AR, but in a cell type-specific manner [Taneja et al.,
2005]. Interestingly, Ser
213 is phosphorylated in AR in
LAPC-4 prostate cancer cells.The LNCaP AR contains
an amino acid mutation in the ligand binding domain
(T877A). Surprisingly, when wild type and mutant ARs
were expressed by transient transfection, the wild type
receptor displayed much more Ser
213 phosphorylation
than did the mutant [Taneja et al., 2005].Thus, the AR
in LNCaP cells likely is minimally phosphorylated on this
site, consistent with a failure to detect phosphorylation
by direct analyses of phosphopeptides.
Phosphorylation site-specific antibodies to phosphorylated
Ser
118 and Ser
167 in ERα have been used to examine
breast cancer specimens. Some studies show a
correlation between phosphorylation of Ser
118 and a
favorable response to Tamoxifen [Murphy et al., 2004],
as well as a correlation between Ser
167 phosphorylation
and response to endocrine therapy [Yamashita et al.,
2005].The studies to date are limited and not all studies
have found such correlations (reviewed in [Murphy et al.,
2006]). Phosphorylation of Ser
118 also correlated with PR
expression, suggesting that the phosphorylation is an
indication that the ERα is active in those samples and
that an ERα antagonist is likely to be beneficial.
Phosphorylation and receptor function
Transcriptional activation
Initially, studies of the role of phosphorylation in receptor
function were limited to measuring transcriptional activity
of transiently transfected reporters. More recent studies
have revealed that receptor phosphorylation contributes
to a variety of functions including receptor stability,
nuclear localization, transcriptional activity, interaction
with coregulators, and other activities such as splicing.
In some cases, the phosphorylation may determine
whether a subsequent posttranslational modification will
occur. As better assays are developed, it is probable that
additional functions will be identified.
Using transient transfection assays to measure the
activities of wild type and mutant receptors, Bai and
Weigel found that an amino-terminal site in chicken PR
(Ser
211) was required for optimal transcriptional activity
and that the hinge site was required for response to low
levels of hormone [Bai et al., 1994; Bai and Weigel, 1996].
Analyses of human PR phosphorylation site mutants
revealed modest reductions in transcriptional activity
[Takimoto et al., 1996]. In contrast, an Ala
294 PR-B mutant
stably transfected into a PR-negative breast cancer cell
line was much less active than the corresponding line
containing a stably transfected wild type receptor,
suggesting that cell context and/or stable rather than
transient transfection alters responsiveness [Daniel et
al., 2007; Qiu and Lange, 2003].Transient transfection
assays of the activities of ERα and AR phosphorylation
mutants also revealed some decreases in activity [Le
Goff et al., 1994; Zhou et al., 1995].
Additional roles for receptor phosphorylation
Analyses of individual receptor functions have revealed
more specific roles for phosphorylation. Mutation of the
phosphorylation sites in GR increases receptor stability
[Webster et al., 1997]. A GR-interacting protein, TSG101,
preferentially interacts with hypophosphorylated GR and
protects it from degradation [Ismaili et al., 2005].
Substitution of an alanine for Ser
294 in human PR
increases receptor stability. PR is degraded by the
proteasome pathway and elimination of the
phosphorylation site decreases ubiquitination of PR,
suggesting that the phosphorylation may serve as a signal
for ubiquitination [Lange et al., 2000]. In ERβ,
phosphorylation of Ser
16 enhances ER degradation
[Cheng et al., 2000].This serine is also a site for
O-GlcNAc modification [Cheng et al., 2000; Cheng and
Hart, 2001].The competing modifications likely regulate
the stability of ERβ.
Phosphorylation can enhance or inhibit protein/protein
interactions. For example, phosphorylations in the amino
terminus of ERβ induced by p42/p44 MAPK enhance
SRC-1 association and induce ligand-independent
activation [Tremblay et al., 1999]. In contrast, activation
of Akt reduces interaction between ERβ and CBP.
Mutation of Ser
255 in ERβ restores CBP binding and blocks
inhibition of ERβ activity by this signaling pathway
[Sanchez et al., 2007].
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localization of receptors. Phosphorylation of Thr
311 in ERα
increases nuclear localization [Lee and Bai, 2002]. In
contrast, stress kinase-induced phosphorylation of Ser
650
in AR enhances cytoplasmic localization [Gioeli et al.,
2006]. Phosphorylation of Ser
294 is required for
EGF-induced nuclear localization of human PR-B, but
not for hormone-dependent nuclear localization [Qiu et
al., 2003]. Phosphatase activity is also required for GR
relocalization to the nucleus, although the target of the
phosphatase is unknown [Dean et al., 2001; Galigniana
et al., 1999].Thus, phosphorylation plays a role in
subcellular distribution of most of the steroid receptors.
Phosphorylation and ERα function
The role of phosphorylation in the regulation of receptor
functions has been most extensively characterized for
ERα and these studies highlight the wide range of kinases
that can phosphorylate a receptor and the diverse roles
for phosphorylation in regulating receptor function. Eight
phosphorylation sites in ERα (serines 104, 106, 118, 167,
236, and 305, Thr311 and Tyr537), distributed throughout
the receptor (see Figure 2), have been identified and
antibodies have been prepared to study their
phosphorylation [Al-Dhaheri and Rowan, 2006].
Phosphorylation of serines 104, 106, and 118 has been
implicated in optimal interaction with several coactivators
[Dutertre and Smith, 2003; Likhite et al., 2006].
Phosphorylation of Ser
118 appears to be particularly
important for physical and/or functional interactions with
a variety of coregulators. It has been implicated in the
interaction with (SF)3a p120, a splicing factor, and the
potentiation of splicing [Masuhiro et al., 2005]. On the
other hand, phosphorylation of this site enhances
interaction with the estrogen receptor repressor SPBP
(stromelysin-1 platelet-derived growth factor-responsive
element-binding protein) [Gburcik et al., 2005]. Ser
167
phosphorylation plays a role in optimal DNA binding in
vitro and in binding to endogenous promoters in vivo
[Castano et al., 1997; Likhite et al., 2006; Shah and
Rowan, 2005]. Ser
236 phosphorylation has been implicated
in inhibition of hormone-independent dimerization and
DNA binding, but this inhibition is overcome by the
addition of estradiol [Chen et al., 1999]. Phosphorylation
of Ser
305 increases transcriptional activity and has been
implicated in preventing acetylation of Lys
303 [Cui et al.,
2004].
Interestingly, Lys
303 is often mutated to Arg in breast
cancer and this mutation has been associated with
hypersensitivity to estrogen [Fuqua et al., 2000]. As
discussed above, phosphorylation of Thr
311 enhances
nuclear translocation [Lee and Bai, 2002].The role of
phosphorylation of Tyr
537 has been controversial [Yudt et
al., 1999]. Mutation of the site alters estradiol binding
kinetics and some amino acid substitutions promote
hormone-independent activation [Weis et al., 1996].
However, these changes may not be a reflection of the
phosphorylation states.In vitro phosphorylation with Src,
which phosphorylates Tyr
537, as well as at least one other
tyrosine, enhances affinity for estradiol [Likhite et al.,
2006]. As more sophisticated means of measuring
receptor functions are developed, it is likely that additional
roles for site-specific receptor phosphorylation will be
identified.
Activation of cell signaling pathways by
steroid hormones
There is abundant evidence that steroids can activate a
variety of cell signaling pathways that influence
transcription and enzyme activities independent of the
genomic activities of the receptors [Watson and Lange,
2005] and, as discussed above, these pathways also
modulate receptor function.These actions are mediated
by steroid receptor family members, as well as by other
proteins that respond to steroids. A detailed discussion
of this aspect of steroid action is beyond the scope of this
review. However, these pathways offer a potential means
of autoregulation of the transcriptional activity of the
receptors. For example, AR and ER interact with Src and
MNAR (modulator of nongenomic actions of the estrogen
receptor) [Haas et al., 2005;Wong et al., 2002]. Hormone
binding results in activation of Src and the downstream
activation of p42/p44 MAPK, kinases that regulate
receptor function through phosphorylation of coactivators
and, in some cases, phosphorylation of the receptors
themselves. PR directly interacts with Src family tyrosine
kinases through a proline-rich motif in the NTD of PR,
which also activates a kinase cascade
[Boonyaratanakornkit et al., 2001]. PR also induces long
term activation of p42/p44 MAPK through induction of
Wnt-1 and the resulting activation of the EGF receptor
[Faivre and Lange, 2007].
Summary
Cell signaling pathways that regulate phosphorylation of
steroid receptors and their coactivators are critical factors
in determining the activities of steroid receptors under
different physiological conditions.While many of the
phosphorylation sites in the steroid receptors and some
of the sites in the coregulators have been identified,
others are still unknown. In particular, there are likely to
be sites that are phosphorylated only in response to a
specific signaling pathway; these phosphorylations may
be transient, but important for specific biological
responses. A number of additional candidate sites have
been identified by in vitro phosphorylation studies. Some
of these sites likely are authentic targets under some
circumstances, while others may be artifacts of the
conditions (high concentrations of purified receptor and
kinase with no competing substrates) and are not
authentic in vivo phosphorylation sites. Moreover,
because phosphorylation studies using high specific
activity γ[
32P] ATP can yield a substantial signal despite
a low percent or stoichiometry for the phosphorylation,
some signals may be due to phosphorylation of a small
amount of denatured receptor.The sites shown in Figure
2 are restricted to those that have been shown to be
phosphorylated in receptors expressed in mammalian or
insect cells. As additional antibodies are generated for
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as genuine sites.
Some sites are targets of multiple kinases, thereby
permitting integration of signals from multiple pathways.
Studies under special conditions (for example, serum-free
medium or activation of a kinase pathway through a stress
signal) can identify a pathway or kinase capable of
phosphorylating a specific site, but these experiments
should be interpreted with caution. Under other
circumstances, another kinase may be the dominant
regulator of the site. Although roles for some
phosphorylation sites have been identified, many others
have not been characterized. Roles for specific sites may
also be context-dependent.This is suggested by the role
of Ser
118 not only in recruiting proteins that contribute to
ERα activation, but also in the recruitment of a repressor
of ERα activity. It is likely that there are phosphorylation
“codes” dependent upon the signaling pathways activated
under a specific physiological condition that determine
the function of the receptor.These alterations will
determine the phosphorylation of specific subsets of
receptor phosphorylation sites, as well as the level of
phosphorylation of coregulators.
While some functions may depend upon a single
phosphorylation, others will have more complex
requirements. For example, EGF-dependent activation
of ERα requires Ser
118 phosphorylation [Bunone et al.,
1996]; although substitution of a negatively-charged
glutamic acid restores responsiveness to EGF, the Glu
118
mutant is not constitutively active.Therefore, at least one
additional EGF-induced modification of receptor or other
proteins is required. In the case of AR, mutation of Ser
650
in the hinge region of AR has been reported to reduce
AR transcriptional activity by about 30% [Zhou et al.,
1995], but this site is also the target of JNK
phosphorylation [Gioeli et al., 2006] and in the context of
activated JNK, phosphorylation of this site reduces AR
activity. As better assays for individual receptor functions
are devised and more phosphorylation site-specific
antibodies for receptors and coregulators are developed,
it is likely that many additional roles for phosphorylation
in receptor function will be identified.
Studies of the regulation of endogenous target genes by
phosphorylation site mutants are likely to reveal target-
and perhaps tissue-specific requirements for
phosphorylations. In contrast to simple transiently
transfected reporters with multiple hormone response
elements, natural targets require receptor interactions
with a variety of other transcription factors and
coregulators to appropriately modify chromatin and induce
transcription.The contributions of individual
phosphorylation sites to overall biological function can
be tested for conserved sites by generating mice with
individual amino acid substitutions and examining their
phenotypes.There is evidence that many, but not all,
phosphorylation sites are conserved.Thus, differential
phosphorylation is also a potential regulator of
species-specific actions of receptors.
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